MarketCap
Facebook
X
Telegram
Dyne Therapeutics Financial Ratios 2025-2011 | DYN
Brief overview of Dyne Therapeutics's valuation multiples
The review covers five available annual periods spanning 2013 to 2020.
Key multiples at the end of the period are P/E 26.24x (median 26.24x), EV/EBITDA 2.88x (median 21.89x), P/S 3.94x (median 2.35x). Ratios sit near their own comparison base, with an average deviation of 0% from five-year medians.
Earnings yield calculated as 1/P/E is about 3.8%, showing current profit per unit of share price.
Current measures of operating quality are ROE -0%, ROA -0%, ROCE -48.2%. Returns below zero mean resources are not producing positive profit. Recovery in operating results is the main reference point.
The cash conversion cycle shortened from 379.8 days to -30.9 days, or 410.7 days. Working capital returns faster.
Overall picture
Dyne Therapeutics trades near its familiar ratio range. A new earnings or profitability trend is needed to change the view.
Annual Financial Ratios Dyne Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
-5914855.8 | -4216533.3 | -6704496.6 | -4852059.3 | -3.0 | -2.3 | - | - | 26.2 | -1.0 | 29.6 | -51.4 | -5.9 | 23.2 | - |
P/S |
- | - | - | - | - | - | - | - | 3.9 | 0.9 | 1.8 | 2.3 | 704.0 | 673.3 | - |
EPS |
-3.5 | -3.4 | -4.0 | -3.2 | -2.9 | -4.1 | -6.1 | - | - | - | - | - | - | - | - |
EV (Enterprise Value) |
1.96 B | 964 M | 1.53 B | 697 M | 299 M | -156 M | 2.4 M | 13.1 M | 9.87 B | 11 B | 8.62 B | 8.21 B | 3.08 B | 4.05 B | 3.02 B |
EBITDA per Share |
-2.83 | -3.34 | -3.91 | -3.04 | -2.89 | -8.37 | - | - | - | - | - | - | - | 7.4 | - |
EV/EBITDA |
-4.2 | -2.8 | -6.4 | -4.1 | -1.8 | 2.9 | - | - | 22.1 | 66.6 | 12.2 | -333.8 | 21.9 | 4.2 | - |
PEG |
480675.72 | - | - | - | - | 0.01 | - | - | 0.25 | 0.0 | 0.17 | -0.6 | 0.01 | 0.22 | - |
P/B |
2.7 | 2.1 | 17.3 | 3.2 | 1.2 | 0.4 | - | - | 1.0 | 0.6 | 0.5 | 1.1 | 1.0 | 0.8 | - |
P/CF |
-6.5 | -4.6 | -8.4 | -5.3 | -3.7 | -2.8 | - | - | 5.5 | 3.4 | -8.2 | -55.5 | 27.4 | -45.9 | - |
ROE % |
-0.00 | -0.00 | -0.00 | -0.00 | -40.55 | -17.36 | - | - | 4.00 | -60.72 | 1.71 | -2.22 | -16.11 | 3.48 | - |
ROA % |
-0.00 | -0.00 | -0.00 | -0.00 | -35.07 | -16.82 | - | - | 0.65 | -9.50 | 0.43 | -0.60 | -6.73 | 1.92 | - |
ROCE % |
-48.16 | -54.60 | -265.26 | -67.74 | -40.75 | -17.13 | - | - | -3.84 | -5.27 | 0.60 | -3.01 | -6.96 | 17.05 | - |
Current Ratio |
5.5 | 11.3 | 2.2 | 5.7 | 7.4 | 31.8 | - | - | 1.5 | 3.3 | 2.4 | 3.9 | 2.3 | 3.0 | - |
DSO |
- | - | - | - | - | - | - | - | 370.0 | 103.1 | 174.3 | 67.2 | 51100.0 | 13140.0 | - |
DIO |
- | - | - | - | - | - | - | - | 55.4 | 71.2 | 107.4 | 66.3 | 57.7 | 137.6 | - |
DPO |
30.9 | 85.0 | 105.2 | 48.1 | - | - | - | - | 45.7 | 53.1 | 52.6 | 68.9 | 104.9 | 152.5 | - |
Operating Cycle |
- | - | - | - | - | - | - | - | 425.4 | 174.3 | 281.7 | 133.5 | 51157.7 | 13277.6 | - |
Cash Conversion Cycle |
-30.9 | -85.0 | -105.2 | -48.1 | - | - | - | - | 379.8 | 121.2 | 229.2 | 64.7 | 51052.8 | 13125.0 | - |
All numbers in USD currency
Quarterly Financial Ratios Dyne Therapeutics
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
-1.08 | -0.73 | -0.76 | -0.97 | -1.05 | - | -0.96 | -0.7 | -0.81 | - | -0.99 | -1.08 | -0.78 | - | -0.8 | -1.01 | -0.69 | - | -0.83 | -0.58 | -0.5 | - | -2.01 | -3.31 | -0.9 | - | -2.36 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA per Share |
-1.09 | -0.75 | -0.8 | -1.01 | -1.07 | - | -1.03 | -0.71 | -0.79 | - | -1.01 | -1.09 | -0.77 | - | -0.81 | - | -0.69 | - | -0.83 | -0.59 | -0.5 | - | -1.92 | -3.13 | -0.88 | - | -1.42 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROE % |
-74.42 | -66.23 | -66.03 | -58.81 | -53.14 | -35.90 | -75.50 | -93.10 | -102.97 | -89.24 | -105.81 | -84.43 | -63.63 | -45.37 | -55.65 | -45.70 | -32.70 | -22.12 | -26.19 | -18.53 | -14.21 | -8.99 | -115.15 | -93.38 | -60.79 | -58.49 | -106.16 | 17.70 | 29.97 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROA % |
-56.82 | -54.86 | -56.30 | -51.72 | -49.08 | -33.09 | -62.42 | -75.60 | -83.03 | -70.46 | -84.27 | -64.11 | -47.42 | -32.11 | -38.52 | -24.71 | -29.79 | -20.61 | -24.55 | -17.97 | -13.79 | -8.71 | -99.37 | -2.54 | -2.23 | - | -90.65 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROCE % |
-77.08 | -69.50 | -69.99 | -62.81 | -57.02 | -38.73 | -79.68 | -96.97 | -106.48 | -92.01 | -108.94 | -86.36 | -64.73 | -45.94 | -56.27 | -46.00 | -32.88 | -22.25 | -26.20 | -18.40 | -14.03 | -8.78 | -34.63 | -2.53 | -2.29 | - | -25.85 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Current Ratio |
3.4 | 5.0 | 5.0 | 4.6 | 13.8 | 11.3 | 12.2 | 16.3 | 11.8 | 2.2 | 3.9 | 5.6 | 6.2 | 5.7 | 6.0 | - | 7.6 | 7.4 | 8.8 | 32.1 | 36.6 | 32.2 | 32.2 | 32.2 | 32.2 | 6.8 | 6.8 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DPO |
36.3 | 36.5 | 52.8 | 49.2 | 29.9 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash Conversion Cycle |
- | - | -52.8 | -49.2 | -29.9 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Multiples are an important financial analysis tool for the company Dyne Therapeutics, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.
Advantages of Using Financial Ratios- Simplified Data Analysis
Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition. - Comparability Between Companies
Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations. - Identification of Trends and Issues
Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks. - Decision Support
Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions. - Accelerated Assessment of Investment Attractiveness
Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.
Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.
Brasil
China
Canada
USA
Britain
India
Singapore
Chile
Bermuda
Argentina
Israel
